Ondine Biomedical (FRA:VF5) EBIT: €-12.83 Mil (TTM As of Dec. 2024)


FRA:VF5 Ondine Biomedical Inc FRA:VF5
47 GF Score
Price €0.15
View Full Analysis

What is Ondine Biomedical EBIT?

Ondine Biomedical FRA:VF5 47 EBIT is €-12.83 Mil as of Dec. 2024. GuruFocus rates FRA:VF5 with a GF Score™ of 47/100.

Ondine Biomedical's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2024 was €-7.58 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was €-12.83 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ondine Biomedical's annualized ROC % for the quarter that ended in Dec. 2024 was -874.23%. Ondine Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -3,296.52%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ondine Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -15.46%.

Ondine Biomedical  (FRA:VF5) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ondine Biomedical's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-15.57 * ( 1 - 0% )/( (1.859 + 1.703)/ 2 )
=-15.57/1.781
=-874.23 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.728 - 1.4 - ( 0.826 - max(0, 2.715 - 2.184+0.826))
=1.859

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.595 - 2.707 - ( 6.547 - max(0, 3.985 - 8.17+6.547))
=1.703

Note: The Operating Income data used here is two times the semi-annual (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Ondine Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-15.164/( ( (0.52 + max(-1.123, 0)) + (0.4 + max(-2.286, 0)) )/ 2 )
=-15.164/( ( 0.52 + 0.4 )/ 2 )
=-15.164/0.46
=-3,296.52 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.157 + 0.873 + 0.324) - (1.4 + 0 + 1.077)
=-1.123

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.307 + 0.853 + 0.426) - (2.707 + 0 + 1.165)
=-2.286

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ondine Biomedical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=-12.829/82.959
=-15.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical EBIT Related Terms

Ondine Biomedical EBIT Historical Data

* Premium members only.

The historical data trend for Ondine Biomedical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical EBIT Chart

Ondine Biomedical Annual Data
Trend Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.13 -33.79 -13.44 -9.83 -12.77

Ondine Biomedical Semi-Annual Data
Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.49 -5.47 -4.44 -5.25 -7.58

FRA:VF5 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Ondine Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ondine Biomedical EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's EV-to-EBIT falls into.


FRA:VF5
47GF Score
Ondine Biomedical Inc FRA:VF5
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ondine Biomedical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-12.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-12.83 Mil mean?
Ondine Biomedical (FRA:VF5) has a EBIT of €-12.83 Mil as of Dec. 2024. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ondine Biomedical.
Is Ondine Biomedical's EBIT too high?
Ondine Biomedical's current EBIT is €-12.83 Mil. Overall, Ondine Biomedical has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's EBIT compare to VRTX and REGN?
Ondine Biomedical's EBIT of €-12.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Ondine Biomedical. Ondine Biomedical's current EBIT is €-12.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Ondine Biomedical (FRA:VF5) has a current EBIT of €-12.83 Mil. The current EBIT is €-12.83 Mil. Ondine Biomedical's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current EBIT is €-12.83 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ondine Biomedical Business Description

Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
47GF Score

Get the complete analysis for FRA:VF5

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price